Corporate Profile
CervoMed is a clinical-stage biotechnology company advancing CNS-focused therapeutics to benefit patients with a range of debilitating neurodegenerative diseases. CervoMed is currently developing neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB) and certain other major neurological disorders.
News Releases
November 13, 2024
November 8, 2024
Events
Nov 1, 2024
Sep 6, 2024 1:50 PM EDT
Jul 23, 2024 10:00 AM EDT